Skeletal muscle atrophy is a poorly understood yet nearly universal consequence of severe human illness for which no therapy currently exists. We hypothesize that a central event in the pathogenesis of skeletal muscle atrophy is increased expression of ATF4, an evolutionarily ancient transcription factor that is induced by stress. This hypothesis is based on several lines of evidence derived from our preliminary studies. First, we found that ATF4 mRNA levels were increased in atrophied skeletal muscle from human subjects with spinal cord injuries. Second, we found that transfection of mouse skeletal muscle with plasmid DNA encoding mouse ATF4 induced myofiber atrophy. Conversely, transfection of an artificial microRNA targeting ATF4 or a dominant negative ATF4 construct reduced myofiber atrophy under fasting conditions. These results identify ATF4 as a novel transcriptional regulator of muscle mass that may be both necessary and sufficient for skeletal muscle atrophy. With the long-term goal of identifying new therapeutic approaches for muscle atrophy in human patients, we propose three aims. First, to determine if ATF4 is essential for muscle atrophy, we will study skeletal muscle-specific ATF4 gene knockout mice and determine if they are resistant to fasting- or denervation- induced muscle atrophy. Second, to determine the upstream mechanism of increased ATF4 expression, we will use RNA interference in wild-type mice and determine if one of the four mammalian stress-activated eIF2alpha kinases is required for ATF4 expression and muscle atrophy. Third, to determine the downstream mechanism(s) of ATF4-mediated atrophy, we will transfect skeletal myotubes with adenovirus expressing ATF4 and determine if this decreases protein synthesis and/or increases protein breakdown. We will also study skeletal muscle-specific ATF4 gene knockout mice to determine if ATF4 is required for induction of atrophy-associated proteins that inhibit protein synthesis (4E-BP1), increase protein synthesis (atrogin-1 and MuRF1), or if ATF4 activates amino acid transporter genes that are essential for muscle atrophy.

Public Health Relevance

Skeletal muscle wasting is a very common medical condition for which no treatment currently exists. We hypothesize that a central cause of skeletal muscle wasting is a protein called ATF4, which acts as a switch that turns on genes for muscle wasting. By studying ATF4 and the genes it regulates, we hope to understand how muscle wasting occurs, and to identify new ways to treat patients with muscle wasting.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Research Project (R01)
Project #
Application #
Study Section
Skeletal Muscle and Exercise Physiology Study Section (SMEP)
Program Officer
Nuckolls, Glen H
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Iowa
Internal Medicine/Medicine
Schools of Medicine
Iowa City
United States
Zip Code
Bullard, Steven A; Seo, Seongjin; Schilling, Birgit et al. (2016) Gadd45a Protein Promotes Skeletal Muscle Atrophy by Forming a Complex with the Protein Kinase MEKK4. J Biol Chem 291:17496-509
Fusakio, Michael E; Willy, Jeffrey A; Wang, Yongping et al. (2016) Transcription factor ATF4 directs basal and stress-induced gene expression in the unfolded protein response and cholesterol metabolism in the liver. Mol Biol Cell 27:1536-51
Bongers, Kale S; Fox, Daniel K; Kunkel, Steven D et al. (2015) Spermine oxidase maintains basal skeletal muscle gene expression and fiber size and is strongly repressed by conditions that cause skeletal muscle atrophy. Am J Physiol Endocrinol Metab 308:E144-58
Ebert, Scott M; Dyle, Michael C; Bullard, Steven A et al. (2015) Identification and Small Molecule Inhibition of an Activating Transcription Factor 4 (ATF4)-dependent Pathway to Age-related Skeletal Muscle Weakness and Atrophy. J Biol Chem 290:25497-511
Adams, Christopher M; Ebert, Scott M; Dyle, Michael C (2015) Use of mRNA expression signatures to discover small molecule inhibitors of skeletal muscle atrophy. Curr Opin Clin Nutr Metab Care 18:263-8
Suneja, Manish; Fox, Daniel K; Fink, Brian D et al. (2015) Evidence for metabolic aberrations in asymptomatic persons with type 2 diabetes after initiation of simvastatin therapy. Transl Res 166:176-87
Fox, Daniel K; Ebert, Scott M; Bongers, Kale S et al. (2014) p53 and ATF4 mediate distinct and additive pathways to skeletal muscle atrophy during limb immobilization. Am J Physiol Endocrinol Metab 307:E245-61
Dyle, Michael C; Ebert, Scott M; Cook, Daniel P et al. (2014) Systems-based discovery of tomatidine as a natural small molecule inhibitor of skeletal muscle atrophy. J Biol Chem 289:14913-24
Bongers, Kale S; Fox, Daniel K; Ebert, Scott M et al. (2013) Skeletal muscle denervation causes skeletal muscle atrophy through a pathway that involves both Gadd45a and HDAC4. Am J Physiol Endocrinol Metab 305:E907-15
Kunkel, Steven D; Elmore, Christopher J; Bongers, Kale S et al. (2012) Ursolic acid increases skeletal muscle and brown fat and decreases diet-induced obesity, glucose intolerance and fatty liver disease. PLoS One 7:e39332

Showing the most recent 10 out of 12 publications